10-Q/A: Greater Cannabis Restates Q1, Reveals Hefty Default Penalties

The Greater Cannabis Company, Inc. restated its Q1 2025 financial results to include significant note default penalties and interest, exacerbating its net loss and highlighting ongoing liquidity challenges.

Summary

• The Greater Cannabis Company, Inc. filed an amended Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2025, to restate its consolidated financial statements.
• The restatement primarily corrects the reflection of terms in a note agreement with FirstFire, recording $138,906 in default penalties and interest as of March 31, 2025.
• The company reported no revenue for the three months ended March 31, 2025, and March 31, 2024.
• Net loss for the three months ended March 31, 2025, increased significantly to $242,417, compared to a net loss of $44,611 for the same period in 2024.
• Operating expenses rose to $43,536 in Q1 2025 from $38,951 in Q1 2024, driven by officers compensation, stock-based compensation, and other operating expenses.
• The company's cash balance decreased to $46,213 as of March 31, 2025, from $57,368 at December 31, 2024.
• Total current liabilities increased to $1,009,103 as of March 31, 2025, from $898,058 at December 31, 2024, primarily due to the newly recorded default penalties.
• The company had negative working capital of $962,890 as of March 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern through March 2026 due to negative cash flows and insufficient capital.
• The company issued 168,000,000 common shares for notes payable conversion and 2,250,000 common shares for compensation during Q1 2025, contributing to dilution.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a significant increase in net loss driven by default penalties, persistent lack of revenue, severe liquidity issues, a 'going concern' warning, and ongoing internal control deficiencies. The need for substantial future capital with no clear path to secure it further compounds the negative outlook.

Positives

• No positive financial or operational developments were explicitly highlighted in the filing; the amendment primarily addresses a restatement due to penalties.

Negatives

• Net loss significantly increased to $242,417 in Q1 2025 from $44,611 in Q1 2024.
• The company recorded $138,906 in note default penalties and interest as of March 31, 2025.
• No revenue was generated in Q1 2025 or Q1 2024.
• Cash balance declined to $46,213 as of March 31, 2025.
• Total current liabilities increased to over $1 million, resulting in negative working capital of $962,890.
• The company used $11,155 cash from operating activities in Q1 2025.
• Internal controls over financial reporting were assessed as not effective as of March 31, 2022, with no changes made during Q1 2025.

Risks

• Inability to remediate identified material weaknesses in internal control over financial reporting and disclosure controls and procedures.
• Failure to meet requirements of business acquisition agreements, potentially leading to loss of operating rights.
• Inability to secure additional financing in the near future to commence and sustain planned development and growth.
• Difficulty attracting, retaining, and motivating qualified personnel, including employees, consultants, and contractors.
• Uncertainties relating to the various industries and operations the company is engaged in.
• Future growth, development, or expansion may not be consistent with expectations from feasibility studies.
• Inherent uncertainty of business operations, including profit, cost of goods, production costs, and potential for unexpected costs and expenses.
• Risks related to commodity price fluctuations.
• Uncertainty of profitability due to a history of losses.
• Failure to obtain adequate financing on a timely basis and on acceptable terms for planned development projects.
• Risks related to environmental regulation and liability.
• Risks related to tax assessments.
• Potential for significant dilution of existing shareholders if additional funds are raised through equity issuance.
• The company's ability to continue as a going concern is in substantial doubt.

Future Outlook

The company's current business plan is to conduct clinical studies on and commercialize a novel cannabinoid-based therapeutic for neuropsychiatric disorders, and to concentrate on cannabis-related investment and development opportunities. Clinical studies for the therapeutic are expected to require an investment of up to $1,000,000 and up to two years to finalize. The company expects to continue incurring negative cash flows until its business generates sufficient cash inflows to finance operations and debt service.

Management Comments

• Management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability, leading to the shift in business model to cannabinoid therapeutic development.
• Management believes that the expectations reflected in the forward-looking statements are reasonable, but cannot guarantee future results, levels of activity, performance or achievements.

Industry Context

The company operates in the evolving and highly regulated cannabis and cannabinoid therapeutic industries. Its shift from general cannabis product commercialization to specialized cannabinoid therapeutics for neuropsychiatric disorders aligns with a trend towards medical and pharmaceutical applications of cannabis compounds, seeking higher value and more defined regulatory pathways compared to recreational or general wellness markets. The focus on clinical studies for conditions like autism, schizophrenia, Parkinson's, and Alzheimer's disease positions the company in a high-potential, but also high-risk and capital-intensive, segment of the biotech industry. The industry is characterized by significant R&D costs, lengthy clinical trial processes, and intense competition, requiring substantial and sustained funding.

Comparison to Industry Standards

• The company's lack of revenue and significant net losses are not uncommon for early-stage biotechnology companies focused on drug development, as substantial capital is typically required for R&D and clinical trials before commercialization.
• However, the magnitude of the accumulated deficit ($4.9 million) and negative working capital ($962,890) relative to its minimal cash balance ($46,213) indicates a severe liquidity crunch, which is worse than typical industry benchmarks for companies actively pursuing clinical development.
• The recording of significant note default penalties and interest, along with a history of converting debt into highly dilutive common stock, suggests financial distress and potentially unfavorable financing terms compared to more established or well-funded peers in the cannabinoid therapeutic space.
• The stated need for up to $1,000,000 for clinical studies over two years is a relatively modest estimate for drug development, which often requires tens or hundreds of millions, suggesting either a very early-stage program or a highly focused initial phase. Companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals), which developed Epidiolex, invested significantly more in their clinical programs.
• The ongoing material weaknesses in internal control over financial reporting are a significant governance concern, falling below the standards expected of publicly traded companies, regardless of size, and could hinder future financing or partnerships.

Corporate Governance

Related Party Transactions

• Loans payable to related parties total $260,000 as of March 31, 2025, consisting of $180,000 from Elisha Kalfa and Yonah Kalfa, and $80,000 from Fernando Bisker and Sigalush, LLC.
• These loans are non-interest bearing and are to be repaid after the company raises at least $1,500,000 from investors or generates sufficient revenue.
• If the first 'Replacement Event' (raising $1.5M) does not occur within 18 months from July 31, 2018, the loans are to be repaid immediately, with an option for lenders to convert to common stock if capital is insufficient.
• The company executed Services Agreements with its Chief Executive Officer for a monthly base salary of $10,000, expensing $30,000 for the three months ended March 31, 2025.

Stakeholder Impact

• **Shareholders:** Significant dilution from ongoing common stock issuances for debt conversion and compensation, coupled with a substantial increase in net loss and a 'going concern' warning, indicates a high risk of further value erosion. The restatement due to default penalties further highlights financial instability.
• **Creditors:** The company's inability to repay related party loans and the incurrence of significant default penalties on third-party notes suggest a high risk of default and potential for further restructuring or conversion of debt to equity.
• **Employees/Management:** Accrued officers compensation of $410,350 suggests deferred payments, which could impact morale and retention. The company's financial instability poses a risk to job security and future compensation.
• **Customers/Partners:** The lack of revenue and shift in business model, along with financial instability, could impact the company's ability to fulfill future commitments or attract new partnerships for its therapeutic development.

Next Steps

• Conduct clinical studies on the novel cannabinoid therapeutic for neuropsychiatric disorders.
• Commercialize the cannabinoid-based therapeutic.
• Concentrate on cannabis-related investment and development opportunities through direct equity investments, joint ventures, licensing agreements, or acquisitions.
• Secure additional funding sources to address liquidity and support planned development and growth.
• Remediate identified material weaknesses in internal control over financial reporting and disclosure controls and procedures, as capital resources permit.

Key Dates

Recommendation

The filing reveals a company in severe financial distress. The restatement to include significant default penalties, coupled with zero revenue, a rapidly increasing net loss, critically low cash reserves, and a 'going concern' warning, paints a dire picture. The persistent material weaknesses in internal controls further erode confidence. While the company has a new strategic focus on cannabinoid therapeutics, it lacks the capital to execute, and its history of highly dilutive debt conversions suggests future financing will come at a significant cost to existing shareholders. The risks far outweigh any potential upside, making it an unfavorable investment.

Keywords

Cannabis, Biotechnology, Neuropsychiatric disorders, Autism, Schizophrenia, Parkinson's disease, Alzheimer's disease, Cannabinoid therapeutics, SEC filing, 10-Q/A, Restatement, Going concern, Liquidity, Clinical studies, Drug delivery